Philippe Bourin

Philippe Bourin

Auto-generated profile, based on publicly available information

Philippe Bourin

CSA21, Toulouse, France

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in Cytotherapy
Verified
Journal Article
Open access
PBPhilippe Bourin
Philippe Bourin
Bruce BunnellBruce Bunnell
Bruce Bunnell
LCLouis Casteilla
Louis Casteilla
MDMassimo Dominici
Massimo Dominici
AKAdam J. Katz
Adam J. Katz
JGJeffrey M. Gimble
Jeffrey M. Gimble
Adipose tissue is a rich and very convenient source of cells for regenerative medicine therapeutic approaches. However, a characterization of the population of adipose-derived stromal and stem cells (ASCs) with the greatest therapeutic potential remains unclear. Under the authority of International Federation of Adipose Therapeutics and International Society for Cellular Therapy, this paper sets out to establish minimal definitions of stromal cells both as uncultured stromal vascular fraction (SVF) and as an adherent stromal/stem cells population. Phenotypic and functional criteria for the identification of adipose-derived cells were drawn from the literature. In the SVF, cells are identified phenotypically by the following markers: CD45-CD235a-CD31-CD34+. Added value may be provided by both a viability marker and the following surface antigens: CD13, CD73, CD90 and CD105. The fibroblastoid colony-forming unit assay permits the evaluation of progenitor frequency in the SVF population. In culture, ASCs retain markers in common with other mesenchymal stromal/stem cells (MSCs), including CD90, CD73, CD105, and CD44 and remain negative for CD45 and CD31. They can be distinguished from bone-marrow-derived MSCs by their positivity for CD36 and negativity for CD106. The CFU-F assay is recommended to calculate population doublings capacity of ASCs. The adipocytic, chondroblastic and osteoblastic differentiation assays serve to complete the cell identification and potency assessment in conjunction with a quantitative evaluation of the differentiation either biochemically or by reverse transcription polymerase chain reaction. The goal of this paper is to provide initial guidance for the scientific community working with adipose-derived cells and to facilitate development of international standards based on reproducible parameters.

21 March 2005 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
BPBénédicte Puissant
Bénédicte Puissant
CBCorinne Barreau
Corinne Barreau
PBPhilippe Bourin
Philippe Bourin
CCCyril Clavel
Cyril Clavel
Jill CorreJill Corre
Jill Corre
ABAntoine Blancher
Antoine Blancher

15 June 2006 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MSMuriel Sudres
Muriel Sudres
FNFrançoIse Norol
FrançoIse Norol
ATAurélIe Trenado
AurélIe Trenado
SGSylvie GrégOire
Sylvie GrégOire
FCFrédÉrIc Charlotte
FrédÉrIc Charlotte
JCJosé L Cohen
José L Cohen
Several reports have suggested that mesenchymal stem cells (MSCs) could exert a potent immunosuppressive effect in vitro, and thus may have a therapeutic potential for T cell-dependent pathologies. We aimed to establish whether MSCs could be used to control graft-vs-host disease (GVHD), a major cause of morbidity and mortality after allogeneic hemopoietic stem cell transplantation. From C57BL/6 and BALB/c mouse bone marrow cells, we purified and expanded MSCs characterized by the lack of expression of CD45 and CD11b molecules, their typical spindle-shaped morphology, together with their ability to differentiate into osteogenic, chondrogenic, and adipogenic cells. These MSCs suppressed alloantigen-induced T cell proliferation in vitro in a dose-dependent manner, independently of their MHC haplotype. However, when MSCs were added to a bone marrow transplant at a MSCs:T cells ratio that provided a strong inhibition of the allogeneic responses in vitro, they yielded no clinical benefit on the incidence or severity of GVHD. The absence of clinical effect was not due to MSC rejection because they still could be detected in grafted animals, but rather to an absence of suppressive effect on donor T cell division in vivo. Thus, in these murine models, experimental data do not support a significant immunosuppressive effect of MSCs in vivo for the treatment of GVHD.

8 March 2007 in Leukemia
Verified
Journal Article
Closed access
PDF file
Jill CorreJill Corre
Jill Corre
KMK Mahtouk
K Mahtouk
MAM Attal
M Attal
MGM Gadelorge
M Gadelorge
AHA Huynh
A Huynh
PBP Bourin
P Bourin

1 February 2000 in Blood
Verified
Journal Article
Open access
JLJean-Jacques Lataillade
Jean-Jacques Lataillade
DCDenis Clay
Denis Clay
CDCatherine Dupuy
Catherine Dupuy
SRSylvain Rigal
Sylvain Rigal
CJClaude Jasmin
Claude Jasmin
MBMarie-Caroline Le Bousse-Kerdilès
Marie-Caroline Le Bousse-Kerdilès
The chemokine stromal cell-derived factor-1 (SDF-1), and its receptor, CXCR-4, have been implicated in the homing and mobilization of human CD34+ cells. We show here that SDF-1 may also be involved in hematopoiesis, promoting the proliferation of human CD34+ cells purified from normal adult peripheral blood (PB). CXCR-4 was expressed on PB CD34+ cells. The amount of CXCR-4 on PB CD34+ cells was 10 times higher when CD34+ cells were purified following overnight incubation. CXCR-4 overexpression was correlated with a primitive PB CD34+ cell subset defined by a CD34high CD38lowCD71lowc-KitlowThy-1+antigenic profile. The functional significance of CXCR-4 expression was ascertained by assessing the promoting effect of SDF-1 on cell cycle, proliferation, and colony formation. SDF-1 alone increased the percentage of CD34+ cells in the S+G2/M phases and sustained their survival. In synergy with cytokines, SDF-1 increased PB CD34+ and CD34highCD38low cell expansion and colony formation. SDF-1 also stimulated the growth of colonies derived from primitive progenitors released from quiescence by anti–TGF-β treatment. Thus, our results shed new light on the potential role of this chemokine in the stem cell engraftment process, which involves migration, adhesion, and proliferation. Furthermore, both adhesion-induced CXCR-4 overexpression and SDF-1 stimulating activity may be of clinical relevance for improving cell therapy settings in stem cell transplantation.

1 February 2014 in Cytotherapy
Verified
Journal Article
Closed access
ABAlessandra Bura
Alessandra Bura
VPValerie Planat-Benard
Valerie Planat-Benard
PBPhilippe Bourin
Philippe Bourin
JSJean-Sébastien Silvestre
Jean-Sébastien Silvestre
FGFabian Gross
Fabian Gross
LCLouis Casteilla
Louis Casteilla